BPC-157 5mg + TB-500 5mg (blend) Quick Reference (10 mg vial)
Research context: mechanisms, human and preclinical evidence, limitations and precautions are in How this works and References. The calculator (Spanish) converts any other volume.
BPC-157 5mg + TB-500 5mg (blend) Dosage Chart (10 mg vial)
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Evidence: only preclinical data are published for BPC-157 5mg + TB-500 5mg (blend); the schedules in the chart are reference schedules and do not come from a human trial.
Standard / Gradual Approach (2 mL = ~5 mg/mL)
| Week / phase | Daily dose | Each peptide | Units per injection (mL) |
|---|---|---|---|
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 12 units (0.12 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 16 units (0.16 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 12 units (0.12 mL) |
Frequency: Once daily, subcutaneously, at a consistent time.
Reconstitution Steps
- Draw 2 mL of bacteriostatic water with a sterile syringe.1
- Inject slowly down the vial wall; avoid shaking to prevent foaming.2
- Gently swirl or roll until fully dissolved (clear solution).3
- Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.4
Advanced / Aggressive Approach (Acute Injury Support) (2 mL = ~5 mg/mL)
| Week / phase | Daily dose | Each peptide | Units per injection (mL) |
|---|---|---|---|
| Weeks 1–2 (Aggressive Load) | 1 mg (1000 mcg) | 500 mcg BPC + 500 mcg TB-500 | 20 units (0.20 mL) |
| Weeks 3–4 (High Load) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 16 units (0.16 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 12 units (0.12 mL) |
Frequency: Once daily, subcutaneously, at a consistent time.
Note: The blend contains equal amounts of BPC-157 and TB-500, so the total dose is split evenly between both peptides. For acute injuries some references describe a higher initial loading phase; a small case series in joint injuries reported improvement, but no controlled trial exists.
Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
U-100 Conversion Table (2 mL = 5 mg/mL)
| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 100 injections |
| 5 | 0.05 mL | 250 mcg | 40 injections |
| 10 | 0.10 mL | 500 mcg | 20 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 10 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 6 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 4 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 2 injections |
This section describes which dose a study or reference source used and what it measured. It is not a recommendation or an administration schedule. A trial dose belongs to its population, duration and supervision and does not transfer to anyone outside that context.
Supplies Needed
Straightforward 12- and 24-week planning for a 10 mg vial at 5 mg/mL.
BPC-157 5mg + TB-500 5mg (blend) vials (10 mg each)
- Standard / Gradual Approach, 12 weeks: Minimum 6 vials (53.2 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 11 vials (103.6 mg required).
- Advanced / Aggressive Approach (Acute Injury Support), 12 weeks: Minimum 6 vials (58.8 mg required).
- Advanced / Aggressive Approach (Acute Injury Support), 24 weeks: Minimum 11 vials (109.2 mg required).
U-100 syringes (1 mL)
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.
- Advanced / Aggressive Approach (Acute Injury Support), 12 weeks: 84 new syringes for 84 injections.
- Advanced / Aggressive Approach (Acute Injury Support), 24 weeks: 168 new syringes for 168 injections.
Bacteriostatic water
- Standard / Gradual Approach, 12 weeks: 12 mL total (2 mL per vial) → 4 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 22 mL total (2 mL per vial) → 8 × 3 mL vials.
- Advanced / Aggressive Approach (Acute Injury Support), 12 weeks: 12 mL total (2 mL per vial) → 4 × 3 mL vials.
- Advanced / Aggressive Approach (Acute Injury Support), 24 weeks: 22 mL total (2 mL per vial) → 8 × 3 mL vials.
Alcohol swabs
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.
- Advanced / Aggressive Approach (Acute Injury Support), 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Advanced / Aggressive Approach (Acute Injury Support), 24 weeks: 336 minimum; one box of 100 does not cover the calculation.
Sharps container: one appropriately sized. Stability planning: totals are minimum arithmetic quantities; follow the product documentation for sterility, storage, handling loss and discard timing.
BPC-157 5mg + TB-500 5mg (blend)View in store
Bacteriostatic water 3 mLView in storeStore links may earn a commission. A supplier page is not scientific evidence or proof of suitability for human use.
BPC-157 5mg + TB-500 5mg (blend) Vial and Research Context
- Reconstitute: add 2 mL of bacteriostatic water to produce 5 mg/mL.
- Frequency in the source: once daily, subcutaneously.
- Described range: schedules run from 600 mcg to 1 mg (1000 mcg) per injection.
- Easy measuring: 1 U-100 unit = 0.01 mL = 50 mcg.
- Vial size: the 10 mg label is total nominal content, not a per-injection amount.
- Vial coverage: at 600 mcg per injection one vial supplies 16 injections; at 1 mg (1000 mcg) it supplies 10. These are mass calculations, not storage periods.
Protocol Overview
Quick reference for the schedules shared by the cited literature.
- Frequency: once daily.
- Concentration: 10 mg in 2 mL = 5 mg/mL.
- Unit conversion: 1 U-100 unit = 50 mcg.
Dosing Schedule
The tables keep each approach separate.
- Standard / Gradual Approach: 600 mcg, 800 mcg, 600 mcg, in phases (once daily).
- Advanced / Aggressive Approach (Acute Injury Support): 1 mg (1000 mcg), 800 mcg, 600 mcg, in phases (once daily).
- Measurement: use the units and mL shown beside each amount.
Storage Instructions
- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.
More detail in the storage guide (Spanish).
Important Notes
- Research only: the referenced compounds are sold for laboratory research. Nothing here is medical advice or an administration schedule.
- Evidence: only preclinical data are published for BPC-157 5mg + TB-500 5mg (blend); the schedules in the chart are reference schedules and do not come from a human trial.
- Above 100 units: a 1 mL U-100 syringe cannot hold them; split across syringes or reconstitute with less volume.
- Accuracy: concentration depends on the actual volume added; measure the diluent with a syringe, not by eye.
- Verification: confirm vial contents against the batch certificate of analysis before calculating.
How This Works
BPC-157 (Body Protection Compound 157):
15-amino-acid pentadecapeptide derived from a protective gastric protein. Stimulates endothelial nitric oxide production, promotes local angiogenesis, and accelerates the healing of tendons, ligaments, and gastrointestinal mucosa. Acts by modulating the nitric oxide system, the VEGFR2 pathway, and expression of genes related to the extracellular matrix.
TB-500 (Thymosin Beta-4 fragment):
Active analog of Thymosin Beta-4. Its main function is to regulate actin, the protein that organizes the cellular cytoskeleton. This regulation allows cells to migrate to the injury site, form new blood vessels (angiogenesis), and rebuild the damaged extracellular matrix.
Sinergia documentada:
While BPC-157 accelerates the first repair phase (inflammation control, cellular recruitment), TB-500 covers the secondary phase (sustained angiogenesis, matrix remodeling). Combined, they cover the full arc of the healing process.
Research Applications
- Lesiones tendinosas y ligamentarias (tendinitis, epicondilitis, lesiones de manguito rotador)
- Lesiones musculares por sobrecarga deportiva
- Post-surgical orthopedic recovery
- Carpal tunnel syndrome and peripheral nerve injuries
- Cardiac recovery post-ischemic event (preclinical research)
- Skin and mucosal healing
Precautions Described in the Literature
Benign profile in preclinical studies. TB-500 has a mild antiplatelet effect: discontinue 48 hours before any surgical procedure. Relative contraindication in active tumors due to pro-angiogenic potential.
Studied Combinations
- Full athletic recovery: BPC+TB blend + CJC No DAC + Ipamorelin for GH support during repair
- Post-trasplante capilar: blend + GHK-Cu for regenerative synergy of graft + follicle
- Intestino + articular: blend + KPV to cover systemic and mucosal inflammation
Injection Technique in Research
- Route in the studies: subcutaneous, in abdominal or thigh adipose tissue, rotating the site.
- Syringe: 1 mL U-100 (100 units); read in units, not mL.
- Asepsis: alcohol swab on the stopper and the site; a new syringe per injection.
- Drawing: purge air, draw the units from the chart and verify before withdrawing the needle from the vial.
Full guide: U-100 syringes and reading units (Spanish).
Research Note
All content on this page is technical and educational. It describes how a vial is reconstituted, how a syringe is read and which amounts the cited sources describe. It does not replace the supervision of a qualified researcher or the judgment of a health professional, and it is not intended to diagnose, treat, cure or prevent any disease.
References
- Modelo preclínico murino
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and its role in healing of gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780.